Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: Results of a randomized, double-blind, placebo-controlled pilot study

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 209-217

  Mainz, Jochen G ^a   Schädlich, Katja ^a   Schien, Claudia ^a   Michl, Ruth ^a   Schelhorn Neise, Petra ^a   Koitschev, Assen ^b   Koitschev, Christiane ^c   Keller, Peter M ^a   Riethmüller, Joachim ^c   Wiedemann, Baerbel ^d   Beck, James F ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b KLINIKUM STUTTGART   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Cystic fibrosis; Nasal lavage; PARI Sinus; Pseudomonas aeruginosa; Sinonasal; SNOT 20; Upper airways

Indexed keywords

CREATININE; PLACEBO; TOBRAMYCIN; AEROSOL; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AEROSOL; ARTICLE; BACTERIAL COLONIZATION; CHILD; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEARING IMPAIRMENT; HUMAN; KIDNEY FUNCTION; LUNG FUNCTION; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NASAL LAVAGE; PARANASAL SINUS; PILOT STUDY; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SINO NASAL OUTCOME TEST 20; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT; YOUNG ADULT; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; MICROBIOLOGY; NOSE MUCOSA;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AEROSOLS; ANTI-BACTERIAL AGENTS; CHILD; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NASAL MUCOSA; PILOT PROJECTS; PSEUDOMONAS AERUGINOSA; TOBRAMYCIN;

EID: 84894697777     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S54064     Document Type: Article

References (29)

1. Sens B, Stern M. (Hrsg) Berichtsband Qualitätssicherung Mukoviszidose 2010 [Quality Record Cystic Fibrosis 2010]: Hippocampus Verlag KG; 2011. German.
2. Doring G, Conway SP, Heijerman HG, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J. 2000;16(4):749-767.
3. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol. 1992;12(3): 158-161.
4. Gysin C, Alothman GA, Papsin BC. Sinonasal disease in cystic fibrosis: clinical characteristics, diagnosis, and management. Pediatr Pulmonol. 2000;30(6):481-489.
5. Mainz JG, Michl R, Pfister W, Beck JF. Cystic fibrosis upper airways primary colonization with Pseudomonas aeruginosa: eradicated by sinonasal antibiotic inhalation. Am J Respir Crit Care Med. 2011;184(9):1089-1090.
6. Mainz JG, Hentschel J, Schien C, et al. Sinonasal persistence of Pseudomonas aeruginosa after lung transplantation. J Cyst Fibros. 2012;11(2):158-161.
7. Hansen SK, Rau MH, Johansen HK, et al. Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection. ISME J. 2011;6(1):31-45.
8. Mainz JG, Naehrlich L, Schien M, et al. Concordant genotype of upper and lower airways P aeruginosa and S aureus isolates in cystic fibrosis. Thorax. 2009;64(6):535-540.
9. Eggesbo HB, Sovik S, Dolvik S, Eiklid K, Kolmannskog F. CT characterization of developmental variations of the paranasal sinuses in cystic fibrosis. Acta Radiol. 2001;42(5):482-493.
10. Aanaes K, Johansen HK, Poulsen SS, Pressler T, Buchwald C, Høiby N. Secretory IgA as a diagnostic tool for Pseudomonas aeruginosa respiratory colonization. J Cyst Fibros. 2013;12(1):81-87.
11. Johansen HK, Aanaes K, Pressler T, et al. Colonisation and infection of the paranasal sinuses in cystic fibrosis patients is accompanied by a reduced PMN response. J Cyst Fibros. 2012;11(6):525-531.
12. Mainz JG, Koitschev A. Pathogenesis and management of nasal polyposis in cystic fibrosis. Curr Allergy Asthma Rep. 2012;12(2):163-174.
13. Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med. 1993;328(24): 1740-1746.
14. St Martin MB, Hitzman CJ, Wiedmann TS, Rimell FL. Deposition of aerosolized particles in the maxillary sinuses before and after endoscopic sinus surgery. Am J Rhinol. 2007;21(2):196-197.
15. Moller W, Saba GK, Haussinger K, Becker S, Keller M, Schuschnig U. Nasally inhaled pulsating aerosols: lung, sinus and nose deposition. Rhinology. 2011;49(3):286-291.
16. Moller W, Schuschnig U, Khadem Saba G, et al. Pulsating aerosols for drug delivery to the sinuses in healthy volunteers. Otolaryngol Head Neck Surg. 2010;142(3):382-388.
17. Mainz JG, Schiller I, Ritschel C, et al. Sinonasal inhalation of dornase alfa in CF: a double-blind placebo-controlled cross-over pilot trial. Auris Nasus Larynx. 2011;38(2):220-227.
18. Gottlieb J, Mattner F, Weissbrodt H, et al. Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis. Respir Med. 2009;103(5):743-749.
19. Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros. 2003;2(1):29-34.
20. Baumann I, Blumenstock G, Zalaman IM, et al. Impact of gender, age, and comorbidities on quality of life in patients with chronic rhinosinusitis. Rhinology. 2007;45(4):268-272.
21. Piccirillo JF, Merritt MG Jr, Richards ML. Psychometric and clinimetric validity of the 20-Item Sino-Nasal Outcome Test (SNOT-20). Otolaryngol Head Neck Surg. 2002;126(1):41-47.
22. Brusasco V, Crapo R, Viegi G. Coming together: the ATS/ERS consensus on clinical pulmonary function testing. Eur Respir J. 2005;26(1): 1-2.
23. Gross M, Berger R, Schonweiler R, Nickisch A. [Auditory processing and perception disorders-diagnostics. Guidelines of the German Society of Phoniatrics and Pedaudiology]. HNO. 2010;58(11):1124-1127. German.
24. Mainz JG, Koitschev A. Management of chronic rhinosinusitis in CF. J Cyst Fibros. 2009;8(S1):10-14.
25. Mak GK, Henig NR. Sinus disease in cystic fibrosis. Clin Rev Allergy Immunol. 2001;21(1):51-63.
26. Aanaes K, von Buchwald C, Hjuler T, Skov M, Alanin M, Johansen HK. The effect of sinus surgery with intensive follow-up on pathogenic sinus bacteria in patients with cystic fibrosis. Am J Rhinol Allergy. 2013;27(1):e1-e4.
27. Albu S. Novel drug-delivery systems for patients with chronic rhinosinusitis. Drug Des Dev Ther. 2012;6:125-132.
28. Muhlebach MS, Miller MB, Moore C, Wedd JP, Drake AF, Leigh MW. Are lower airway or throat cultures predictive of sinus bacteriology in cystic fibrosis? Pediatr Pulmonol. 2006;41(5):445-451.
29. Walter S, Gudowius P, Bosshammer J, et al. Epidemiology of chronic Pseudomonas aeruginosa infections in the airways of lung transplant recipients with cystic fibrosis. Thorax. 1997;52(4):318-321.